Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A hidden-identity GoGlides receipts explainer on Filtronic, profitability, cash, SpaceX orders, and customer-concentration risk.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A hidden-identity GoGlides receipts explainer on Redwire's backlog, defense-UAS wins, cash flow, and dilution risk.
OpenA hidden-identity GoGlides receipts explainer on Sidus Space, balance sheet strength, small revenue, and dilution risk.
OpenA hidden-identity GoGlides receipts explainer on Momentus, the space tow-truck idea, cash, losses, and dilution risk.
OpenMomentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAchieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
OpenTag facets appear after tag usage counts are rebuilt.